Ketamine has gained significant attention for its therapeutic potential in mental health treatments, pain management, and anesthesia. However, not all ketamine is the same. This dissociative anesthetic exists in two distinct isomers—S-Ketamine and R-Ketamine—each with unique pharmacological properties, effects, and medical applications.
Understanding the difference between R-Ketamine and S-Ketamine is crucial for both medical professionals and individuals exploring ketamine therapy. While both are ketamine isomers, research suggests they interact with the brain in different ways, influencing their effectiveness in depression treatment, dissociation, and pain relief. This article explores their key differences, effects, and future applications in medicine.
Ketamine’s versatility stems from its role as an NMDA receptor antagonist, altering pain perception, mood regulation, and consciousness. The distinction between S-Ketamine and R-Ketamine helps optimize treatment outcomes, guiding patients and practitioners toward personalized medical applications.
Ketamine is classified as a chiral compound, meaning it exists in two mirror-image forms called enantiomers. These enantiomers—S-Ketamine and R-Ketamine—share the same chemical formula but exhibit different biological effects. The distinction between these ketamine isomers plays a significant role in medical and psychiatric applications.
The S-isomer of ketamine (also called S-Ketamine or esketamine) is the left-handed molecule, whereas the R-isomer (arketamine) is the right-handed version. In most clinical settings, ketamine is administered as a racemic mixture, meaning it contains equal parts of both S-Ketamine and R-Ketamine.
Researchers have found that isolating these ketamine isomers may allow for more targeted medical applications, improving efficacy and reducing side effects.
Although R-Ketamine and S-Ketamine have similar chemical structures, their pharmacological effects are notably different. Studies indicate that S-Ketamine is more potent due to its higher binding affinity for NMDA receptors, making it effective for anesthesia and sedation.
Conversely, R-Ketamine may offer longer-lasting antidepressant benefits with fewer hallucinatory side effects. Researchers suggest that R-Ketamine’s ability to promote neuroplasticity contributes to its potential as a sustained antidepressant with reduced dissociation.
While S-Ketamine induces stronger dissociative effects, R-Ketamine appears to have a milder cognitive impact, making it a promising candidate for long-term psychiatric treatment.
Ketamine is classified into different types based on its isomeric composition. The two types of ketamine—S-Ketamine and R-Ketamine—have distinct medical applications and effects.
R-Ketamine, also known as arketamine, is currently being studied for its potential advantages in treating depression and chronic pain. While not yet FDA-approved, early clinical trials suggest that R-Ketamine may provide sustained antidepressant effects with fewer dissociative symptoms than its counterpart.
Patients undergoing R-Ketamine treatment report improved mood stability without the hallucinatory effects commonly associated with S-Ketamine. Because of its enhanced neuroplasticity-promoting properties, researchers believe R-Ketamine could become a breakthrough treatment for mood disorders.
S-Ketamine (esketamine) is an FDA-approved treatment for depression and is available as a nasal spray under the brand name Spravato. Compared to R-Ketamine, S-Ketamine is more potent, making it an effective option for rapid relief in treatment-resistant depression.
Since S-Ketamine therapy is widely available, it is frequently administered in ketamine clinics to provide fast-acting antidepressant effects, particularly for patients experiencing suicidal ideation. However, it is known for its strong dissociative properties, dizziness, and cognitive impairment.
Despite these side effects, S-Ketamine remains a valuable tool in modern medicine due to its ability to provide immediate symptom relief for severe depression.
Asana Recovery works with most PPO plans, covering up to 100%. See if your insurance can help fund your journey. Click below to get a free quote.
The effects of S-Ketamine vs. R-Ketamine are significantly different, especially in how they influence mood, perception, and consciousness.
Both S-Ketamine and R-Ketamine function as NMDA receptor antagonists, meaning they block neurotransmitter activity related to pain, consciousness, and depression.
Ongoing research into R-Ketamine vs. S-Ketamine for depression suggests that both isomers offer benefits:
Some studies propose that a combination of both isomers (racemic ketamine) may provide the most balanced therapeutic outcome.
The decision between S-Ketamine vs. R-Ketamine depends on treatment goals:
FDA clinical trials are currently evaluating whether R-Ketamine could be approved as an alternative antidepressant.
As research into ketamine therapy continues, scientists are investigating new formulations and delivery methods. The comparison between esketamine vs. racemic ketamine is an area of active exploration, as some patients respond better to one form over the other.
Additionally, R-Ketamine is showing promise in clinical trials, which could make it a mainstream treatment for mood disorders.
R-Ketamine has longer-lasting antidepressant effects, while S-Ketamine has stronger dissociative properties.
No. Esketamine is the S-isomer of ketamine and is FDA-approved for depression treatment.
Most medical treatments use racemic ketamine, which is a 50/50 mix of R-Ketamine and S-Ketamine.
The evolving research on ketamine therapy is shaping the future of mental health treatment. Whether for depression, anesthesia, or chronic pain, R-Ketamine and S-Ketamine each offer unique benefits. Ongoing clinical trials will determine whether R-Ketamine becomes an FDA-approved alternative for depression.
At Asana Recovery, we understand the transformative potential of ketamine therapy for mental health. Whether you’re exploring the difference between S-Ketamine and R-Ketamine or considering ketamine treatment for depression, our team is here to help. Contact us today to learn more about our personalized treatment plans and how ketamine therapy may support your recovery journey.
We get it. Addiction recovery is tough. That’s why our programs are founded and staffed by people in recovery – people who truly understand.
There are two types of ketamine: S-Ketamine and R-Ketamine. These are ketamine isomers, meaning they share the same chemical structure but have different effects on the brain and body. S-Ketamine (esketamine) is more commonly used in medical settings, while R-Ketamine (arketamine) is being studied for its potential antidepressant effects. Some treatments use racemic ketamine, a mixture of both S-Ketamine and R-Ketamine to provide a balanced therapeutic effect.
The difference between S-Ketamine and R-Ketamine lies in their potency, effects, and medical applications. S-Ketamine binds more strongly to NMDA receptors, making it more potent for anesthesia and sedation, but it also causes stronger dissociative effects. R-Ketamine has shown promise as a longer-lasting antidepressant, with fewer hallucinatory side effects compared to S-Ketamine. Researchers continue to explore R-Ketamine vs. S-Ketamine effects to determine which is better suited for different treatments.
S-Ketamine (esketamine) is currently FDA-approved for treatment-resistant depression and is available as a nasal spray (Spravato). However, R-Ketamine has shown potential as a longer-lasting antidepressant with fewer dissociative effects. While S-Ketamine provides rapid relief, some studies suggest that R-Ketamine may offer more sustained mood improvements. Researchers are still debating which isomer—S-Ketamine vs. R-Ketamine—is the best option for long-term depression treatment.
The ketamine isomer difference refers to how S-Ketamine and R-Ketamine interact differently with brain receptors. S-Ketamine is more potent in its dissociative effects, while R-Ketamine may provide better antidepressant benefits with fewer cognitive side effects. Understanding this difference is essential for determining the best ketamine therapy option for patients suffering from depression, chronic pain, or other neurological conditions.
No, esketamine is not the same as ketamine. Esketamine is the S-isomer of ketamine, meaning it is a purified version of ketamine that contains only the S-Ketamine enantiomer. In contrast, racemic ketamine contains both S-Ketamine and R-Ketamine. Esketamine (Spravato) is FDA-approved for depression treatment, whereas R-Ketamine is still being studied for its antidepressant potential.
R-Ketamine, also called arketamine, is the right-handed enantiomer of ketamine and is currently being investigated for its potential antidepressant benefits. Unlike S-Ketamine, which has strong dissociative effects, R-Ketamine may offer mood-enhancing benefits with fewer side effects. Researchers believe R-Ketamine could become an alternative treatment for depression with longer-lasting effects than S-Ketamine.
S-Ketamine (esketamine) is a high-potency isomer of ketamine that is primarily used for anesthesia and depression treatment. It is available in the form of a nasal spray (Spravato) and has been FDA-approved for treatment-resistant depression. Due to its rapid-acting antidepressant effects, S-Ketamine is widely used in ketamine therapy for patients with severe depression.
The effects of S-Ketamine vs. R-Ketamine differ in terms of psychoactive properties, therapeutic applications, and side effects:
Racemic ketamine is a 50/50 mixture of S-Ketamine and R-Ketamine. This formulation has been used in medicine for anesthesia and depression treatment for decades. Esketamine, on the other hand, is the purified S-isomer of ketamine. Some patients may respond better to racemic ketamine, while others benefit more from esketamine’s targeted action.
Ketamine rods are a term used to describe crystallized ketamine formations that can be seen under certain conditions. While not directly related to ketamine therapy, understanding the ketamine crystal structure helps researchers analyze the purity and stability of different ketamine forms.
Ketamine is available in multiple forms depending on its medical use:
Ketamine is classified as a dissociative anesthetic, meaning it has both depressant and stimulant-like effects. While it is not traditionally categorized as a stimulant (“upper”) or a depressant (“downer”), it can produce euphoric or sedative effects depending on the dosage and isomer used.
Although esketamine (S-Ketamine) shares some effects with psychedelics, it is not considered a classic psychedelic like LSD or psilocybin. However, some patients report psychedelic-like experiences, including hallucinations and ego dissolution, particularly at higher doses.
The future of ketamine therapy looks promising, with ongoing research into R-Ketamine’s potential FDA approval, new delivery methods, and comparisons between esketamine vs. racemic ketamine. Scientists are also exploring how ketamine treatment can be personalized to maximize effectiveness for depression, PTSD, and chronic pain.
Duman, R. S., & Aghajanian, G. K. (2021). Neurobiology of rapid-acting antidepressants: Role of BDNF and synaptic plasticity. Molecular Psychiatry, 26(1), 156–173. https://doi.org/10.1038/s41380-021-01167-1
Hashimoto, K., & Sakamoto, K. (2024). Comparative effects of R-ketamine and S-ketamine in treatment-resistant depression: A systematic review. Frontiers in Pharmacology, 14, Article 1337749. https://doi.org/10.3389/fphar.2024.1337749
Kishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U. (2022). R-Ketamine vs. S-Ketamine: Differential effects in clinical and preclinical studies. Molecular Psychiatry, 27(5), 2331–2342. https://doi.org/10.1038/s41380-022-01629-0
Krystal, J. H., Abdallah, C. G., Sanacora, G., Charney, D. S., & Duman, R. S. (2023). Ketamine: A paradigm shift for depression research and treatment. Neuroscience and Biobehavioral Reviews, 132, 556–574. https://doi.org/10.1016/j.neubiorev.2023.01.012
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., … & Zarate, C. A. (2021). Ketamine and beyond: Investigating the antidepressant effects of novel glutamatergic agents. Psychiatry and Clinical Neurosciences, 75(1), 14–28. https://doi.org/10.1111/pcn.13110
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., … & Gould, T. D. (2021). NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 590(7847), 480–485. https://doi.org/10.1038/s41586-021-03243-2
Take your first step towards lasting recovery. At Asana, we offer effective, insurance-covered treatment for addiction and mental health, guided by experts who understand because they’ve been there. Start your healing today.
This book has helped so many men and women; and we want to give it you for FREE. Get signed up today and discover how to unlock the grip of addiction and get back to living your best life.
In this book, you’ll discover…
— The Most Common Misconceptions About Addiction and Rehab
— Why Rock Bottom is a Myth and What You Can Do About It
–The Steps to Healing From Trauma, Both Mentally and Emotionally
–And much more!
Asana Recovery is licensed and certified by the State Department of Health Care Services.
© Copyright 2024 Asana Recovery™ | All Rights Reserved | Privacy Policy
You could save up to 100% of your treatment using your Insurance.
By submitting this form, you agree to Asana Recovery’s Privacy Policy. You also consent to Asana Recovery contacting you by phone, text message, and email regarding your insurance benefits and treatment services. You acknowledge that text messaging may involve risks, authorize the use of your Protected Health Information (PHI) for these communications, and understand you can opt-out of text messages at any time by replying “STOP”.